JAK2 and myelofibrosis: The CXCL12/CXCR4 pathway can be induced by oncogenic JAK2, which frequently suffers activating mutations in primary myelofibrosis, and JAK2 inhibition can reduce the chemotaxis of hematopoietic cells isolated from primary myelofibrosis [20].